Optimizing Treatment for Patients With Relapsed/Refractory Multiple Myeloma in the Era of Bispecific Antibodies

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.